5-amino-1mq research centers on its role as a selective, membrane-permeable small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT). By blocking NNMT in cellular and animal models, this compound prevents the irreversible methylation of nicotinamide, preserving intracellular nicotinamide adenine dinucleotide (NAD+) pools and enhancing mitochondrial respiration during metabolic evaluations.
5-amino-1mq research centers on its role as a selective, membrane-permeable small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT). By blocking NNMT in cellular and animal models, this compound prevents the irreversible methylation of nicotinamide, preserving intracellular nicotinamide adenine dinucleotide (NAD+) pools and enhancing mitochondrial respiration during metabolic evaluations.
Nicotinamide N-methyltransferase (NNMT) is a cytosolic enzyme responsible for catalyzing the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide (NAM), producing 1-methylnicotinamide (MNA) and S-adenosylhomocysteine (SAH). In metabolic research, NNMT over-expression is strongly correlated with compromised cellular bioenergetics, reduced mitochondrial density, and altered lipid deposition. The development of membrane-permeable small-molecule inhibitors has enabled targeted exploration of NNMT suppression in cell cultures and rodent models.
Among these targeted small molecules, 5-amino-1mq research has gained significant prominence within metabolic and endocrinological literature. As a derivative of quinoline, 5-amino-1-methylquinolinium acts as a charge-neutralized, cell-permeable transition-state analog that competitive binds the catalytic site of NNMT. By inhibiting this enzymatic node, investigators can evaluate the downstream effects on intracellular NAD+ availability, cellular energy expenditure, and adipocyte remodeling without modulating upstream receptor-mediated pathways.
To understand the core 5 amino 1mq mechanism, investigators must analyze the intersection of the salvage pathway for NAD+ synthesis and methyl donor flux. Under baseline conditions, NNMT methylates excess nicotinamide, routing it away from the NAD+ salvage pathway toward urinary excretion as MNA. This reaction permanently consumes a molecule of SAM, lowering the methyl donor pool required for histones and DNA methylation while simultaneously starving the salvage enzyme nicotinamide phosphoribosyltransferase (NAMPT) of its primary substrate.
When introduced into isolated adipocyte or skeletal muscle cell assays, 5-Amino-1MQ directly inhibits NNMT with high kinetic specificity. Inhibiting NNMT preserves local nicotinamide availability, feeding substrate directly into NAMPT for conversion to nicotinamide mononucleotide (NMN) and subsequently NAD+. In vitro measurements demonstrate that blocking NNMT leads to a significant increase in intracellular NAD+ content, elevated S-adenosylmethionine to S-adenosylhomocysteine (SAM/SAH) ratios, and an upregulation of sirtuin 1 (SIRT1) enzyme activity. Researchers interested in broader metabolic signaling pathways can explore detailed comparative datasets within the PX1 Research Library Hub.
In metabolic research, 5-Amino-1MQ is frequently evaluated alongside mitochondrial-derived peptides and AMP-activated protein kinase (AMPK) activators. While 5-Amino-1MQ acts specifically as an enzymatic inhibitor of NNMT, alternative research compounds target parallel metabolic checkpoints. Understanding how these compounds differ in target specificity, bioenergetic yield, and pathway engagement is critical for designing rigorous double-blind in vitro or animal studies.
For example, mitochondrial-derived peptides like MOTS-c research protocols target nuclear transcription factors to promote insulin sensitivity and folate-dependent purine synthesis. Similarly, direct AMPK activators such as AICAR research compounds induce phosphorylation of downstream metabolic regulators independently of NAD+ salvage dynamics. Newer estrogen-related receptor agonists like SLU-PP-332 drive oxidative muscle fiber conversion by directly activating ERRα, ERRβ, and ERRγ receptors. In contrast, researchers utilizing high-purity 5-Amino-1MQ reagent focus specifically on preserving methyl donor capacity and substrate availability within the salvage pathway, demonstrating how enzyme inhibition offers a distinct therapeutic model from direct agonist signaling.
Preclinical studies evaluating high-fat-diet (HFD) rodent models demonstrate that NNMT expression is upregulated in white adipose tissue (WAT) and liver parenchymal cells. When treated with 5-amino-1mq research compounds, diet-induced obese mice exhibited reduced body weight gain and marked reductions in adipocyte volume without alterations in daily caloric intake. This phenotype is attributed to an increased basal metabolic rate driven by uncoupled mitochondrial oxidation in adipose depots.
In vitro data indicate that 5-amino-1mq treatment enhances oxygen consumption rates (OCR) in primary adipocytes, accompanied by up-regulated transcript expression of uncoupling protein 1 (UCP1) and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α). These findings suggest that blocking NNMT facilitates the phenotypic browning of white adipose tissue into beige-like adipocytes, rendering the reagent a valuable tool for investigating energy expenditure, mitochondrial biogenesis, and non-shivering thermogenesis.
A common query among clinical bioenergetic researchers centers on the availability of 5-amino-1mq human trials. Currently, published literature on 5-amino-1mq is restricted entirely to in vitro cell assays, ex vivo tissue models, and preclinical animal investigations (primarily murine models of obesity, muscle atrophy, and metabolic dysregulation). There are no published, peer-reviewed phase I, II, or III human clinical trials establishing human pharmacokinetic, pharmacodynamic, or safety profiles for this compound.
Because 5-amino-1mq human trials have not been conducted under regulatory investigational framework, the molecule remains exclusively a tool for laboratory research use only. Academic laboratories and private institutions sourcing 5-Amino-1MQ must handle the compound strictly within exploratory experimental protocols. To review secondary literature on cellular NAD+ preservation and metabolic signaling cascades, consult our specialized analysis on NAD+ pathway mechanisms.
Because small-molecule inhibitors must achieve high structural purity to avoid off-target kinase or methyltransferase inhibition, verifying reagent quality is non-negotiable in scientific research. Contaminants or unreacted synthetic intermediates can introduce confounding cytotoxicity into cell viability assays or distort spectrophotometric measurements of enzymatic kinetics.
To ensure precise experimental reproducibility, principal investigators must insist on full analytical transparency. PX1 Research adheres to stringent manufacturing and analytical benchmarks across all analytical standards and catalog research peptides.
Key quality criteria for laboratory-grade 5-Amino-1MQ include:
• Chemical Identity & Purity: Verified via High-Performance Liquid Chromatography (HPLC) to guarantee ≥98% purity.
• Molecular Mass Confirmation: Confirmed by Mass Spectrometry (MS) to validate exact molecular weight and chemical structure.
• Endotoxin Control: Kinetic chromogenic LAL assays verifying endotoxin content strictly below 0.01 EU/mg to prevent inflammatory signaling in cell culture models.
• Domestic Synthesis & Quality Assurance: Manufactured in GMP-compliant, ISO 17025 certified facilities within the United States.
• Lot Traceability: Certificate of Analysis (COA) provided per individual lot number with full raw spectral data attached.
• Reliable Logistics: Ships same-day (Monday through Friday) directly from state-of-the-art dispatch hubs in California and Arizona to maintain supply chain integrity for institutional research labs requiring bulk research supply agreements.
5-Amino-1MQ (5-amino-1-methylquinolinium) is typically supplied as a lyophilized or crystalline iodide or bromide salt. Achieving complete solubilization requires careful selection of laboratory solvents based on the intended assay environment. 5-Amino-1MQ exhibits limited solubility in purely aqueous buffers at high stock concentrations, requiring organic solvents for initial stock preparation.
For cell culture assays, initial stock solutions are typically prepared in dimethyl sulfoxide (DMSO) or high-grade dimethylformamide (DMF) up to concentrations of 10 to 20 mM. Once fully dissolved, stock solutions can be diluted into culture media or phosphate-buffered saline (PBS), ensuring final DMSO concentrations remain below 0.1% (v/v) to prevent vehicle cytotoxicity. Lyophilized powders should be stored at -20°C in a desiccated container, protected from light. Reconstituted organic stock aliquots are stable at -80°C for extended periods; repeated freeze-thaw cycles must be avoided to prevent chemical degradation.
Beyond direct bioenergetic measurements, 5 amino 1mq research provides critical insights into epigenetic regulation. NNMT acts as a metabolic sink for methyl groups. By consuming SAM, elevated NNMT activity decreases the SAM/SAH ratio, which serves as the primary thermodynamic driver for DNA methyltransferases (DNMTs) and histone methyltransferases (HMTs).
Preclinical studies indicate that inhibiting NNMT with 5-Amino-1MQ restores intracellular SAM levels, subsequently increasing histone H3 lysine 4 trimethylation (H3K4me3) at specific gene promoters involved in oxidative phosphorylation. Researchers examining cellular aging, senescence, and epigenetic reprogramming utilize 5-Amino-1MQ to interrogate how metabolic substrate flux directly influences nuclear chromatin structure and gene transcription patterns.
When designing protocols involving 5-amino-1mq research, experimental conditions must account for cell-type-specific NNMT expression levels. High baseline NNMT expression is observed in differentiated adipocytes, hepatocytes, and specific cancer cell lines, whereas undifferentiated myoblasts exhibit lower constitutive expression. Dose-response curves should evaluate NNMT inhibition across a range of 1 µM to 50 µM in vitro to determine optimal IC50 values without inducing non-specific cytotoxicity.
In vivo studies utilizing animal models typically administer the compound via intraperitoneal injection or oral gavage formulated in specialized co-solvent vehicles (such as saline containing 5% DMSO and 10% Solutol HS-15). Researchers tracking bioenergetic outcomes generally monitor systemic blood glucose, plasma lipid panels, adipocyte cross-sectional area, tissue-specific NAD+/NADH ratios, and mitochondrial DNA copy number across longitudinal treatment schedules.
What is the current status of 5-amino-1mq human trials?
There are currently no published, peer-reviewed 5-amino-1mq human trials. All available empirical literature on 5-Amino-1MQ is derived from in vitro cellular assays and preclinical animal models. The compound is designated strictly for laboratory research use.
What is the primary 5 amino 1mq mechanism in cellular models?
The core 5 amino 1mq mechanism involves competitive inhibition of nicotinamide N-methyltransferase (NNMT). By blocking NNMT, 5-Amino-1MQ prevents the conversion of nicotinamide to 1-methylnicotinamide, preserving intracellular NAD+ levels and maintaining the SAM/SAH methyl donor ratio.
How does 5-amino-1mq research differ from direct NAD+ precursor supplementation?
While NAD+ precursors like NMN or NR supply building blocks for NAD+ synthesis, 5-amino-1mq research focuses on preventing the active degradation and excretion of nicotinamide by inhibiting the enzyme NNMT. This approach targets the metabolic sink rather than solely increasing substrate input.
What animal models have been utilized in 5 amino 1mq research?
5-amino 1mq research has primarily utilized diet-induced obese (DIO) murine models, aged rodent models evaluating skeletal muscle regeneration, and xenograft models exploring altered tumor metabolism.
Is 5-Amino-1MQ water-soluble for laboratory buffer preparation?
5-Amino-1MQ standard salts exhibit moderate solubility in aqueous buffers but solubilize significantly better in organic solvents such as DMSO or DMF. Researchers typically prepare stock solutions in 100% DMSO before diluting into aqueous media for assay work.
What purity levels are required for valid 5-Amino-1MQ preclinical research?
Preclinical in vitro and in vivo studies require high chemical purity (≥98%) verified by analytical RP-HPLC and Mass Spectrometry. Contaminants can cause off-target toxicity or interfere with enzymatic kinetics.
How does 5-Amino-1MQ influence adipocyte thermogenesis in vitro?
In cell culture studies, treatment with 5-Amino-1MQ increases intracellular NAD+ and activates SIRT1, leading to upregulated expression of thermogenic genes such as UCP1 and PGC-1α, promoting phenotypic browning in white adipocytes.
How should reconstituted 5-Amino-1MQ stock solutions be stored?
Stock solutions dissolved in DMSO should be aliquoted into single-use microcentrifuge tubes and stored at -80°C. Repeated freeze-thaw cycles must be avoided to prevent thermal and chemical degradation.
What is the endotoxin limit for laboratory-grade 5-Amino-1MQ?
For reliable cellular and animal research, 5-Amino-1MQ reagents should test below 0.01 EU/mg for bacterial endotoxins using kinetic chromogenic LAL analysis to avoid triggering immune responses.
Can 5-Amino-1MQ be evaluated alongside mitochondrial peptides like MOTS-c?
Yes. Researchers frequently design multi-target metabolic protocols evaluating 5-Amino-1MQ alongside mitochondrial peptides like MOTS-c or AMPK activators like AICAR to investigate distinct nodes in energy metabolism.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.